28.81
0.24 (0.84%)
| Previous Close | 28.57 |
| Open | 28.82 |
| Volume | 6,052 |
| Avg. Volume (3M) | 21,940 |
| Market Cap | 51,387,876 |
| Price / Sales | 2.12 |
| Price / Book | 3.89 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Profit Margin | -15.45% |
| Operating Margin (TTM) | -17.43% |
| Diluted EPS (TTM) | -2.06 |
| Quarterly Revenue Growth (YOY) | 43.60% |
| Total Debt/Equity (MRQ) | 19.09% |
| Current Ratio (MRQ) | 0.760 |
| Operating Cash Flow (TTM) | 1.06 M |
| Levered Free Cash Flow (TTM) | 1.76 M |
| Return on Assets (TTM) | -10.90% |
| Return on Equity (TTM) | -25.29% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Precipio, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | 3.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.40 |
|
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. It focuses on improving cancer diagnostics, particularly hematologic malignancies. Its objective is to enhance diagnostic accuracy and accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, and Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division and the Products Division. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 14.13% |
| % Held by Institutions | 7.46% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |